Comprehensive analysis of lncRNAs as biomarkers for diagnosis, prognosis, and treatment response in clear cell renal cell carcinoma

• Published in: Molecular therapy. Oncolytics 2021-09, Vol.22, p.209-218
• Main Authors: Chao, Xiaoyu, Wang, Pei, Ma, Xiaoyu, Li, Zhenfen, Xia, Yubing, Guo, Ying, Ge, Linna, Tian, Linzhu, Zheng, Hong, Du, Yaowu, Li, Jitian, Zuo, Zhanjie, Xie, Longxiang, Guo, Xiangqian
• Format: Article
• Language: English
• Subjects: biomarker; ccRCC; ceRNA; diagnosis; lncRNAs; miRNA; oncogene; Original; prognosis; treatment response; tumor suppressor
• ISSN: 2372-7705; 2372-7705
• DOI: 10.1016/j.omto.2021.08.003

Clear cell renal cell carcinoma (ccRCC) is the most common histological type of renal carcinoma and has a high recurrence rate and poor outcome. Accurate patient risk stratification based on genetic markers can help to identify the high-risk patient for early and further treatments and would promote patient survival. Long non-coding RNAs (lncRNAs) have attracted widespread attention as biomarkers for early diagnosis, treatment, and prognosis because of their high specificity and sensitivity. Here, we performed a systematic search in NCBI PubMed and found 44 lncRNAs as oncogenes, 18 lncRNAs as tumor suppressors, 199 lncRNAs as diagnostic biomarkers, 62 lncRNAs as prognostic biomarkers, and 3 lncRNAs as predictive biomarkers for ccRCC. We also comprehensively discuss the biological functions and molecular regulatory mechanisms of lncRNAs in ccRCC. Overall, the present study is a systemic analysis to assess the expression and clinical value of lncRNAs in ccRCC, and lncRNAs hold promise to be diagnostic, prognostic, and predictive biomarkers. [Display omitted] lncRNAs play important roles in ccRCC. Here, Chao et al. write a systematic review to summarize and discuss the mechanisms, abnormal expressions, and clinical applications of lncRNAs in ccRCC, which provides a comprehensive insight into the research field of molecular regulatory mechanisms of lncRNAs in ccRCC.